Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 Mar;69(3):520–524. doi: 10.1038/bjc.1994.94

Defining a high mortality risk group among women with primary breast cancer.

T Nordén 1, A Lindgren 1, R Bergström 1, L Holmberg 1
PMCID: PMC1968840  PMID: 8123483

Abstract

Increasing interest has been focused on DNA ploidy, hormone receptor status and tumour size as prognostic factors in node-negative breast cancer. We analysed these factors in patients operated on for primary invasive breast cancer between January 1981 and December 1987 in a prospective study of 248 women with no involved axillary nodes and 188 women with positive nodes followed until 15 April 1989. Oestrogen or progesterone receptor negativity, aneuploidy and tumour diameter exceeding 20 mm were studied as negative prognostic signs in life table analyses and Cox proportional hazards models of corrected survival. Corrected survival decreased with increasing number of negative signs. Three to four signs yielded a statistically significant, two- to threefold higher risk than the others. Survival estimates by life table analyses differed by 20% at 5 years. In the whole group, women with three or four negative factors had a relative risk of dying from their disease more than twice that of the others. Women with no involved nodes and with three or four negative factors had a risk of dying from breast cancer similar to that of node-positive women with fewer than three.

Full text

PDF
520

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Auer G. U., Caspersson T. O., Wallgren A. S. DNA content and survival in mammary carcinoma. Anal Quant Cytol. 1980 Sep;2(3):161–165. [PubMed] [Google Scholar]
  2. Clark G. M., Dressler L. G., Owens M. A., Pounds G., Oldaker T., McGuire W. L. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med. 1989 Mar 9;320(10):627–633. doi: 10.1056/NEJM198903093201003. [DOI] [PubMed] [Google Scholar]
  3. De Vita V. T., Jr Breast cancer therapy: exercising all our options. N Engl J Med. 1989 Feb 23;320(8):527–529. doi: 10.1056/NEJM198902233200812. [DOI] [PubMed] [Google Scholar]
  4. Duffy S. W., Tabar L., Fagerberg G., Gad A., Gröntoft O., South M. C., Day N. E. Breast screening, prognostic factors and survival--results from the Swedish two county study. Br J Cancer. 1991 Dec;64(6):1133–1138. doi: 10.1038/bjc.1991.477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fisher E. R., Redmond C., Fisher B., Bass G. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Projects (NSABP). Prognostic discriminants for 8-year survival for node-negative invasive breast cancer patients. Cancer. 1990 May 1;65(9 Suppl):2121–2128. doi: 10.1002/1097-0142(19900501)65:9+<2121::aid-cncr2820651408>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  6. Gelbfish G. A., Davidson A. L., Kopel S., Schreibman B., Gelbfish J. S., Degenshein G. A., Herz B. L., Cunningham J. N. Relationship of estrogen and progesterone receptors to prognosis in breast cancer. Ann Surg. 1988 Jan;207(1):75–79. doi: 10.1097/00000658-198801000-00015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Haybittle J. L., Blamey R. W., Elston C. W., Johnson J., Doyle P. J., Campbell F. C., Nicholson R. I., Griffiths K. A prognostic index in primary breast cancer. Br J Cancer. 1982 Mar;45(3):361–366. doi: 10.1038/bjc.1982.62. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hillner B. E., Smith T. J. Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model. N Engl J Med. 1991 Jan 17;324(3):160–168. doi: 10.1056/NEJM199101173240305. [DOI] [PubMed] [Google Scholar]
  9. McGuire W. L., Tandon A. K., Allred D. C., Chamness G. C., Clark G. M. How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst. 1990 Jun 20;82(12):1006–1015. doi: 10.1093/jnci/82.12.1006. [DOI] [PubMed] [Google Scholar]
  10. Sigurdsson H., Baldetorp B., Borg A., Dalberg M., Fernö M., Killander D., Olsson H. Indicators of prognosis in node-negative breast cancer. N Engl J Med. 1990 Apr 12;322(15):1045–1053. doi: 10.1056/NEJM199004123221505. [DOI] [PubMed] [Google Scholar]
  11. Strang P., Lindgren A., Stendahl U. Comparison between flow cytometry and single cell cytophotometry for DNA content analysis of the uterine cervix. Acta Radiol Oncol. 1985 Jul-Aug;24(4):337–341. doi: 10.3109/02841868509136062. [DOI] [PubMed] [Google Scholar]
  12. Todd J. H., Dowle C., Williams M. R., Elston C. W., Ellis I. O., Hinton C. P., Blamey R. W., Haybittle J. L. Confirmation of a prognostic index in primary breast cancer. Br J Cancer. 1987 Oct;56(4):489–492. doi: 10.1038/bjc.1987.230. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Wrange O., Nordenskjöld B., Gustafsson J. A. Cytosol estradiol receptor in human mammary carcinoma: an assay based on isoelectric focusing in polyacrylamide gel. Anal Biochem. 1978 Apr;85(2):461–475. doi: 10.1016/0003-2697(78)90243-9. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES